Increased EMA/Industry Dialogue Needed to Address Upcoming Biopharm Regulatory Challenges, Retiring Quality Director Purves Says
Aug 21st, 2010
Please Log in to print the full article
The biopharmaceutical regulatory challenges confronting the EMA over the next decade – from biosimilars, advanced therapies, personalized medicine and transgenics to variations and quality by design – will require close industry/regulator dialogue and new communication...
You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.